Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.
about
Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionHeterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical TrialsHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Vaccine design for CD8 T lymphocyte responsesLong peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.Characterization of a single-cycle rabies virus-based vaccine vector.Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.IIIa deleted adenovirus as a single-cycle genome replicating vector.Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene.Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in miceAmplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virusA replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rheReplicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.Replication-Competent Controlled Herpes Simplex Virus.Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.Replicating and non-replicating viral vectors for vaccine developmentAdenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.Problems and emerging approaches in HIV/AIDS vaccine development.Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys.Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challengeComparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.XVII International AIDS Conference: From Evidence to Action - Clinical and biomedical prevention science.Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses.IL-18 expression results in a recombinant vaccinia virus that is highly attenuated and immunogenicA novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus.Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.Expression of human rotavirus chimeric fusion proteins from replicating but non disseminating adenovectors and elicitation of rotavirus-specific immune responses in mice.Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection.Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.Flagellin in fusion with human rotavirus structural proteins exerts an adjuvant effect when delivered with replicating but non-disseminating adenovectors through the intrarectal route.Single-cycle adenovirus vectors in the current vaccine landscape.Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors.Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development
P2860
Q27001897-C4DC3A8B-66F0-42D0-9384-B19BA4EC686BQ28394899-A0C3DDEF-DE1D-417A-BFED-37F8A7FD5C80Q30381447-A713B12F-83F1-4140-BDF1-FB9235D77351Q30411492-D8092068-6159-45DD-82D9-3FFB1408858FQ33578049-1A47960E-C0EE-4F8F-8B2A-4875331B2A1CQ33676502-2CD4B779-0170-4322-8553-D0C23709EC6BQ33872445-55FA77E4-7071-44D2-A59E-AF8A0B1B53EBQ34016756-CDDD7C50-4EDA-4FEB-B133-4578D0708819Q34471962-C9842751-5B1E-4B5A-BA41-2A55200C2478Q34700810-A5DB0141-4B6A-443A-BCC7-5EFB4BD5A451Q34992681-0972374A-8E4A-4D36-A0E1-66FFB77970B5Q35021632-2924026F-A121-4DB8-9651-3A1A62973D0BQ35160124-90F80E64-38C2-45A3-A885-E1C73ADFD8A2Q35675044-42BE31BE-A544-420D-8DC6-3F4B3A529DF6Q35785031-199A0BBD-9A48-4B26-A060-DF2B4C2BA5C1Q35940685-603F7D69-4DDF-4961-8EE7-3101E05C4437Q36086213-61232945-D670-42DA-A6B4-CCC8AA80E1DAQ36141610-B1F41F9A-4FF7-4ED2-B9AF-487FD2A6C5A6Q36464587-BF01151D-F935-43C8-9659-1A2E87F56159Q36625165-07DB9A94-289D-4237-8A6A-30306AAC3429Q36758574-38E62476-9CA2-49E2-B9C0-007577A9DCB2Q36827361-AE9921CF-75FB-44E5-ABC0-16199127E290Q36949703-8DEA5D7B-0D05-4FF0-B5B5-E113979CA153Q36961218-27281FB2-4668-48B8-A6BB-A816AA2EFEE7Q37033311-5FB6136B-6CFC-46AB-B648-26A2B5FC4280Q37096865-A85ADA3A-4C59-42B3-8839-42D319525B52Q37297052-FAC8CF15-BB5B-475F-BB9D-9AC4E3465915Q37347813-8115D5DB-7A02-4A25-B48F-A360F97F313BQ37380345-079DB07E-8CAD-4401-9CAF-EBF14CA9C8E0Q37560829-828DCE53-3A7F-4DA3-B609-6071F1BE907CQ37617613-171D98CD-5E52-433D-A0C8-D2B650B9DEDAQ38353693-47AFAA68-EC99-4A1B-921F-60A302E2ECA2Q38728732-58D742A4-22B8-4A78-9DCF-AADC20457996Q39190586-5704A8DA-BEF6-49F9-969E-13B69AC74903Q39310460-1CCDCFA9-40A5-48B5-8F7D-B5C02E330C56Q41759578-397C8A8E-6C98-456C-A69E-C12F6FC695FBQ42253366-28F92262-9C83-49BF-92AC-95DFBE208CDEQ47282517-9FFC68FE-5942-4607-826D-ED2E2C0F33E7Q53692345-BEADC291-4BC5-4A1A-B69E-5EBB55801A25Q56993265-A8B084BB-6052-41B8-AF03-D688880E7085
P2860
Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Replicating rather than nonrep ...... priming high-titer antibodies.
@ast
Replicating rather than nonrep ...... priming high-titer antibodies.
@en
type
label
Replicating rather than nonrep ...... priming high-titer antibodies.
@ast
Replicating rather than nonrep ...... priming high-titer antibodies.
@en
prefLabel
Replicating rather than nonrep ...... priming high-titer antibodies.
@ast
Replicating rather than nonrep ...... priming high-titer antibodies.
@en
P2093
P2860
P1433
P1476
Replicating rather than nonrep ...... priming high-titer antibodies.
@en
P2093
Alberta Davis-Warren
David Venzon
Elaine Kan
Indresh Srivastava
Krishna K Murthy
Liqun Rejean Wang
Marjorie Robert-Guroff
Susan W Barnett
P2860
P304
10200-10209
P356
10.1128/JVI.79.16.10200-10209.2005
P407
P577
2005-08-01T00:00:00Z